859 related articles for article (PubMed ID: 33925129)
21. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.
Pan J; Mendes LP; Yao M; Filipczak N; Garai S; Thakur GA; Sarisozen C; Torchilin VP
Eur J Pharm Biopharm; 2019 Mar; 136():18-28. PubMed ID: 30633973
[TBL] [Abstract][Full Text] [Related]
22. Can nanomedicines kill cancer stem cells?
Zhao Y; Alakhova DY; Kabanov AV
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1763-83. PubMed ID: 24120657
[TBL] [Abstract][Full Text] [Related]
23. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in nanotheranostics for triple negative breast cancer treatment.
Thakur V; Kutty RV
J Exp Clin Cancer Res; 2019 Oct; 38(1):430. PubMed ID: 31661003
[TBL] [Abstract][Full Text] [Related]
25. Receptor-Targeted Surface-Engineered Nanomaterials for Breast Cancer Imaging and Theranostic Applications.
Ahmad J; Rizwanullah M; Suthar T; Albarqi HA; Ahmad MZ; Vuddanda PR; Khan MA; Jain K
Crit Rev Ther Drug Carrier Syst; 2022; 39(6):1-44. PubMed ID: 35997100
[TBL] [Abstract][Full Text] [Related]
26. iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors.
Zhao P; Dong S; Bhattacharyya J; Chen M
Mol Pharm; 2014 Aug; 11(8):2703-12. PubMed ID: 24960465
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Approaches of Dual-targeted Nanomedicines for Tumor Multidrug Resistance.
Han W; Shen Z; Zou J; Ye Q; Ge C; Zhao Y; Wang T; Chen Y
Curr Drug Deliv; 2024; 21(2):155-167. PubMed ID: 37143266
[TBL] [Abstract][Full Text] [Related]
28. Innovative nanotheranostics: Smart nanoparticles based approach to overcome breast cancer stem cells mediated chemo- and radioresistances.
Kola P; Nagesh PKB; Roy PK; Deepak K; Reis RL; Kundu SC; Mandal M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(4):e1876. PubMed ID: 36600447
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
30. Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.
Bai M; Shen M; Teng Y; Sun Y; Li F; Zhang X; Xu Y; Duan Y; Du L
Oncotarget; 2015 Dec; 6(41):43779-90. PubMed ID: 26575421
[TBL] [Abstract][Full Text] [Related]
31. Nanosoldiers: A promising strategy to combat triple negative breast cancer.
Pawar A; Prabhu P
Biomed Pharmacother; 2019 Feb; 110():319-341. PubMed ID: 30529766
[TBL] [Abstract][Full Text] [Related]
32. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
J Cell Physiol; 2020 Sep; 235(9):6230-6245. PubMed ID: 32017076
[TBL] [Abstract][Full Text] [Related]
33. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
34. β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.
Bar-Zeev M; Kelmansky D; Assaraf YG; Livney YD
Eur J Pharm Biopharm; 2018 Dec; 133():240-249. PubMed ID: 30367935
[TBL] [Abstract][Full Text] [Related]
35. Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy.
Murugan C; Rayappan K; Thangam R; Bhanumathi R; Shanthi K; Vivek R; Thirumurugan R; Bhattacharyya A; Sivasubramanian S; Gunasekaran P; Kannan S
Sci Rep; 2016 Oct; 6():34053. PubMed ID: 27725731
[TBL] [Abstract][Full Text] [Related]
36. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.
Milane L; Ganesh S; Shah S; Duan ZF; Amiji M
J Control Release; 2011 Oct; 155(2):237-47. PubMed ID: 21497176
[TBL] [Abstract][Full Text] [Related]
37. Recent progress in nanomedicine for enhanced cancer chemotherapy.
Wei G; Wang Y; Yang G; Wang Y; Ju R
Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
[TBL] [Abstract][Full Text] [Related]
38. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
39. Overcoming multidrug resistance with nanomedicines.
Ganoth A; Merimi KC; Peer D
Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
[TBL] [Abstract][Full Text] [Related]
40. Nanomedicines for combating multidrug resistance of cancer.
Zhu YX; Jia HR; Duan QY; Wu FG
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1715. PubMed ID: 33860622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]